J. Garau Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

R. Dumke, H. von Baum, P.C. Lück, E. Jacobs

L. Boyanova Clinical Microbiology and Infection

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler

P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

A.K. Reddy, P. Garg, I. Kaur Clinical Microbiology and Infection

In-vitro susceptibility and molecular characterisation of macrolide resistance mechanisms among Streptococcus pneumonia isolates in The Netherlands: the.

R. Cantón Clinical Microbiology and Infection

Genital Chlamydia trachomatis infections

P. Nordmann, L. Poirel Clinical Microbiology and Infection

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program M.

Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant.

Clinical Microbiology and Infection

W. Witte, B. Pasemann, C. Cuny Clinical Microbiology and Infection

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

D.E. Low Clinical Microbiology and Infection

Vector control: a cornerstone in the malaria elimination campaign

Sofie Arens, Jan Verhaegen, Ludo Verbist

G. Höffken Clinical Microbiology and Infection

Community-acquired pneumonia: the evolving challenge

Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals C. Nonhoff, O. Denis,

CMI editorial report 2011 Clinical Microbiology and Infection

Elements of design: the knowledge on which we build

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

J. S. Oxford, S. Bossuyt, S. Balasingam, A. Mann, P. Novelli, R

Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic.

Antimicrobial susceptibility in Escherichia coli of human and avian origin—a comparison of wild-type distributions M. Sjölund, S. Bengtsson, J. Bonnedahl,

Levofloxacin in the treatment of ventilator-associated pneumonia

Building in efficacy: developing solutions to combat drug‐resistant S

R. Bitterman, M. Paul, D. Polak, Y. Geffen

Metagenomics and probiotics

M. Aires-de-Sousa Clinical Microbiology and Infection

N. Maggi-Solcà, C. Valsangiacomo, J.-C. Piffaretti

Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant.

T.M. File Clinical Microbiology and Infection

Update on antifungal resistance in Aspergillus and Candida

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

Antibacterial drug discovery in the 21st century

Abstracts cont. Clinical Microbiology and Infection

A.W. Karchmer Clinical Microbiology and Infection

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

P.M. Hawkey Clinical Microbiology and Infection

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

Current experience in treating invasive zygomycosis with posaconazole

Reducing antibiotic use in influenza: challenges and rewards

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

B.A. Cunha Clinical Microbiology and Infection

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands J.W. Mouton, A.R. Jansz Clinical.

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Presentation transcript:

Performance in practice: bacteriological efficacy in patients with drug‐resistant S. pneumoniae J. Garau Clinical Microbiology and Infection Volume 10, Pages 28-35 (January 2004) DOI: 10.1111/j.1470-9465.2004.00860.x Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Distribution of patients and S. pneumoniae isolates. (a) Bacteriology ITT population. (b) Bacteriology PP follow‐up population. Clinical Microbiology and Infection 2004 10, 28-35DOI: (10.1111/j.1470-9465.2004.00860.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Amoxicillin susceptibility (susceptible ≤ 2 mg/L, intermediate 4 mg/L, resistant ≥ 8 mg/L) of PRSP isolated in the bacteriology PP population at follow up (N = 52) from the amoxicillin/clavulanate 2000/125 mg treatment group. Clinical Microbiology and Infection 2004 10, 28-35DOI: (10.1111/j.1470-9465.2004.00860.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 3 Efficacy of amoxicillin/clavulanate 2000/125 mg in patients with S. pneumoniae vs. comparators (bacteriology PP population at follow up). Clinical Microbiology and Infection 2004 10, 28-35DOI: (10.1111/j.1470-9465.2004.00860.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 4 Efficacy of amoxicillin/clavulanate 2000/125 mg in patients with PRSP (bacteriology PP population at follow up). Clinical Microbiology and Infection 2004 10, 28-35DOI: (10.1111/j.1470-9465.2004.00860.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 5 Efficacy of amoxicillin/clavulanate 2000/125 mg in patients with PRSP, by indication (bacteriology PP population at follow up). Clinical Microbiology and Infection 2004 10, 28-35DOI: (10.1111/j.1470-9465.2004.00860.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions